In this study, researchers will observe and study the data from participants with hemophilia A who receive damoctocog alfa pegol as prescribed by their doctors. Participants will not receive any advice or changes to their healthcare during the study.
Hemophilia A is a genetic bleeding disorder. It is caused by the lack of a protein called clotting factor 8 (FVIII) that helps blood to clot properly. Lack of FVIII can result in excessive blood loss or bleeding inside the body after being injured or having surgery.
The study drug, damoctocog alfa pegol, can be used to prevent or treat bleeding episodes by replacing missing FVIII in the body of people with hemophilia A. It is already approved for people with hemophilia A who are at least 12 years old and have previously used other hemophilia A treatments.
Through this study, researchers want to learn more about its safety in a real-world setting.
The participants will receive damoctocog alfa pegol as prescribed by their doctors during routine practice according to the approved product information.
The main purpose of this study is to learn more about how safe damoctocog alfa pegol is in Korean participants with hemophilia A who previously used other hemophilia A treatments. To do this, researchers will collect information about any medical problems participants have during their treatment.
Data will be collected from December 2023 to March 2026 and cover a period of about 8 months for each participant. Data will come from participants' health records and information collected during their routine clinic visits.
In this study, only available data from routine care will be collected. No visits or tests are required as part of this study.

开始日期2024-01-24

申办/合作机构

Bayer AG

NCT05643560 / RecruitingN/A

Long-term Treatment Outcome of Jivi® Prophylaxis on Joint Health in Adult Patients With Hemophilia A

This is an observational study in which data from people with hemophilia A who decide on their own or by recommendation of their doctors to take Jivi are collected and studied. In observational studies, only observations are made without specified advice or interventions.
Hemophilia A is a genetic bleeding disorder that is caused by the lack of a protein in the blood called "clotting factor 8" (FVIII). FVIII is naturally found in the blood where it causes the blood to clump together to help prevent and stop bleeding. People with lower levels of FVIII or with FVIII that does not work properly may bleed for a long time from minor wounds, have painful bleeding into joints, or have internal bleeding.
The study treatment, Jivi (also called damoctocog alfa pegol), is already available for doctors to prescribe to people with hemophilia A to treat and prevent bleeding. It works by replacing the missing FVIII, or the FVIII that does not work properly.
People with hemophilia A need frequent injections of FVIII products into the vein. So called standard half-life (SHL) products need to be given 2 to 4 times a week for the prevention of bleeding. In recent years, new products like Jivi called extended half-life (EHL) products have available. These products last longer in the body so that they require to be given less often with injections up to every 7 days. Thus, these treatments may be easier and more comfortable to stick to in daily life. There is no general plan concerning the best amount of treatment and the frequency of injections for the prevention of bleeding, since the severity may be different and individual risk factors have to be considered. Doctors often decide on a treatment plan based on patient's disease and response.
Clinical studies have already shown that people with hemophilia A benefit from the treatment with Jivi. However, there are no data available coming from the real-world about how well Jivi works to support joint health, measured by ultrasound (US) examination and HEAD-US score.
In this study, researchers want to learn more about how well Jivi works if used for prolonged periods of treatment under real-world settings to prevent problems with joints in people with hemophilia A. How well it works means to find out if participants' joints status can be improved by treatment with Jivi.
To do this, researchers will collect data about participants' joints status by
making images of participants' joints by using sound waves (ultrasound), and
using HEAD-US score after 24 months of treatment with Jivi. The researchers will then compare these data to the participants' joints status before treatment start with Jivi.
Besides this data collection, no further tests or examinations are planned in this study.
Some participants in this study will already be receiving treatment with Jivi as part of their regular care no more than 12 months. And some participants will start to take Jivi in this study as prescribed by their doctors during routine practice according to the approved product information.
The researchers will collect data from each patient for a period of 26 months after initiation of the Jivi treatment.
There are no required visits or tests in this study.

开始日期2022-12-29

申办/合作机构

Bayer AG

NCT05036278 / Recruiting临床4期

A Multicenter, Prospective, Open-label, Clinical Study to Assess the Effect of Using a New Risk Score Approach to Select the Most Appropriate Prophylaxis Regimen for Reaching a Favorable Outcome, When Hemophilia A Patients Switch From Standard Half-life Products to Damoctocog Alfa Pegol (Jivi)

Researchers are looking for a better way to treat people who have hemophilia A. Hemophilia A is a genetic bleeding disorder that is caused by the lack of a protein in the blood called "clotting factor 8" (FVIII). FVIII is naturally found in the blood where it causes the blood to clump together to help prevent and stop bleeding. People with lower levels of FVIII or with FVIII that does not work properly may bleed for a long time from minor wounds, have painful bleeding into joints, or have internal bleeding.
The study treatment, Jivi (also called damoctocog alfa pegol), is already available for doctors to prescribe to people with hemophilia A to treat and prevent bleeding. It works by replacing the missing FVIII, or the FVIII that does not work properly.
People with hemophilia A need frequent injections of FVIII products into the vein. So called standard half-life (SHL) products need to be given 2 to 4 times a week for the prevention of bleeding. In recent years, new products like Jivi called extended half-life (EHL) products have become available. These products last longer in the body so that they require to be given less often with injections every 3-5 days. Thus, these treatments may be easier and more comfortable to stick to in daily life. There is no general plan concerning the best amount of treatment and the frequency of injections for the prevention of bleeding, since the severity may be different and individual risk factors have to be considered. Doctors often decide on a treatment plan based on their experience.
The main purpose of this study is to learn how well a new scoring approach works to select a treatment plan for the prevention of bleeding in people with hemophilia A who switch their treatment from SHL products to Jivi. Different types of information are used to calculate the risk score like bleeding history, certain biological factors, and physical activity of the participant.
All participants will receive Jivi for 6 months.
In the first four weeks, all participants will receive Jivi 2 times a week at a dose level of 40 IU per kilogram body weight (also known as 40 IU/kg/dose, recommended maximum dose is 6,000 IU). Then, based on their risk score, each participant will be assigned to one of three treatment plans:
participants with a high risk remain on Jivi administration 2 times a week at 40 IU/kg/dose
participants with a medium risk will switch to Jivi administration every 5 days at 50 IU/kg/dose
participants with a low risk will switch to Jivi administration every 5 days at 50 IU/kg/dose and after 4 weeks to a less frequent administration (e.g., every 7 days) at 60 IU/kg/dose To check how well the new scoring approach works for choosing the right treatment plan, researchers will look at how many participants have a favourable outcome.
This means that the participant has either fewer bleeding events vs. the pre-study treatment and takes Jivi less often or as often as the previous SHL treatment but with fewer bleeding events, or that the participant has a comparable number of bleeding events but needs to take Jivi less often than the previous treatment. Each participant will be in the study for approximately 7.5 months. During this time, 4 visits to the study site and 3 phone calls are planned. During the study, the doctors and their study team will: • do physical examinations • take blood samples • ask the participants questions about how they are feeling and what adverse events they are having. In addition, participants or their guardians are required to write down the dates of Jivi treatments and bleeding events in an electronic diary and to fill in different questionnaires on their quality of life, health status, work/ school productivity, pain, and treatment satisfaction. In addition, participants are expected to keep appointments for visits and to adhere to the assigned treatment regimen.
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.

开始日期2022-07-28

申办/合作机构

Bayer AG

100 项与 Damoctocog Alfa Pegol 相关的临床结果

登录后查看更多信息

100 项与 Damoctocog Alfa Pegol 相关的转化医学

登录后查看更多信息

100 项与 Damoctocog Alfa Pegol 相关的专利（医药）

登录后查看更多信息

项与 Damoctocog Alfa Pegol 相关的文献（医药）

2024-02-01·European Journal of Haematology

Interim analyses of the multinational real‐world prospective cohort HEM‐POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A

Article

作者: Reding, Mark T ; Matsushita, Tadashi ; Álvarez-Román, María Teresa ; Oldenburg, Johannes ; Schmidt, Kathrin ; Meijer, Karina ; Castaman, Giancarlo ; Janbain, Maissaa

Abstract:

Objectives:

To assess effectiveness and safety of damoctocog alfa pegol in interim analyses of the ongoing real‐world hemophilia A HEM‐POWR study.

Methods:

HEM‐POWR (NCT03932201) is a multinational Phase 4 prospective observational study. The primary objective was annualized bleeding rate (ABR) in previously treated patients (PTPs) with hemophilia A. Secondary objectives included adverse events and number of affected joints.

Results:

At data cut‐off (August 17, 2022), the safety analysis set included 268 patients and the full analysis set (FAS) included 161 patients. The most common dosing regimen during observation period was prophylaxis (FAS = 158/161, 98.1%) every 3–4 days (twice weekly; FAS = 78/158, 49.4%) and a median (min, max) infusion dose of 37.5 (10, 72) IU/kg. PTPs receiving prophylactic damoctocog alfa pegol have fewer infusions compared with prior treatment. Median total ABR (Q1, Q3) was 0.0 (0.0, 1.8) and mean total ABR (SD) was 2.4 (8.2). The proportion of patients with no affected joints increased between initial visit and follow‐up. No FVIII inhibitors, treatment‐related adverse events, or deaths were reported.

Conclusions:

Damoctocog alfa pegol shows effectiveness and acceptable safety, as well as consistent utilization, in real‐world PTPs with hemophilia A, including in patients with non‐severe hemophilia and those with a history of inhibitors. Please see video for a summary of this study.

2023-11-01·European Journal of Haematology

Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect comparison method

Article

作者: Corrales-Medina, Fernando F ; Kessler, Craig M ; Tarantino, Michael D ; Jiménez-Yuste, Víctor ; Mannucci, Pier Mannuccio

Abstract:

Objectives:

We aimed to indirectly compare the efficacy of personalized prophylaxis with simoctocog alfa (Nuwiq®) versus three extended half‐life (EHL) recombinant FVIII (rFVIII) concentrates.

Methods:

Treatment effects were compared using matching‐adjusted indirect comparisons after matching individual patient‐level baseline characteristics for simoctocog alfa (pharmacokinetic [PK]‐guided personalized prophylaxis) against published aggregate personalized prophylaxis data for efmoroctocog alfa, damoctocog alfa pegol, and rurioctocog alfa pegol.

Results:

A higher percentage (p < .001) of patients with zero bleeds was found with simoctocog alfa compared with efmoroctocog alfa (75% vs. 45%), damoctocog alfa pegol (77% vs. 38%), and rurioctocog alfa pegol (target trough level 1%–3%; 78% vs. 42%). Similar efficacy was found comparing simoctocog alfa against rurioctocog alfa pegol 8%–12% (77% vs. 62%). The mean total annualized bleeding rate was lower (p < .001) with simoctocog alfa than damoctocog alfa pegol (1.5 vs. 4.9). Consistent with approved dosing, the mean FVIII weekly dose was higher (p < .001) for simoctocog alfa than efmoroctocog alfa, damoctocog alfa pegol, or rurioctocog alfa pegol 1%–3%, but lower (p < .001) than rurioctocog alfa pegol 8%–12%.

Conclusions:

Indirect comparisons demonstrated that PK‐guided, personalized prophylaxis with simoctocog alfa can lead to higher zero bleed rates compared with personalized EHL rFVIII concentrate regimens, albeit with higher weekly doses, and a lower percentage of patients treated twice weekly or less.

2023-08-22·Pharmaceuticals (Basel, Switzerland)

Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey.

Article

作者: Zanon, Ezio

Hemophilia A is characterized by a deficiency of clotting factor VIII (FVIII) requiring lifelong prophylactic treatment, typically with recombinant FVIII. In recent years, drugs with extended half-lives have become available, including damoctocog alfa pegol (Bayer S.p.A.). The clinical efficacy and safety of damoctocog alfa pegol were demonstrated in the PROTECT VIII phase II/III development program. To assess the physicians' experience and to collect data on prophylactic treatment with damoctocog alfa pegol, a monitoring survey was carried out among 15 Italian hemophilia centers. A total of 149 patients on treatment with damoctocog alfa pegol for at least 6 months were considered. Zero bleeds were reported in 75% of patients treated with damoctocog alfa pegol in the last 6 months; zero hemarthroses were reported in 82% of the same patients. Overall, 86% of patients with damoctocog alfa pegol reduced their monthly infusions. The estimated average reduction in IU/kg during prophylaxis with damoctocog alfa pegol, both monthly and annually, was around 17.5%. All involved clinicians were satisfied with damoctocog alfa pegol. Survey results suggest that damoctocog alfa pegol reduced the number of weekly infusions, annual bleeding, and joint bleeding rate in the majority of patients, improving joint health and patients' quality of life.

项与 Damoctocog Alfa Pegol 相关的新闻（医药）

2024-02-29

·BioSpace

Baisong Mei’s Immigrant Journey Through American Biopharma

Pictured: Baisong Mei/Nicole Bean for BioSpace Baisong Mei is no stranger to leadership roles. At just 15 years old, he was already in medical school leading a group of students 10 years his senior. (In China, medical students skip undergraduate degrees and instead go straight to a doctoral program.) That was just one of many instances of leadership peppered throughout the career of Editas’s current chief medical officer. Mei was born in a small town in the southern part of Anhui province in China. He skipped grades a couple of times, which allowed him to start college at Bengbu Medical College (now Bengbu Medical University) at just 15 years old, the first time in his life he went to a bigger city, Bengbu. Because he had done well in high school, scored reasonably well on the college entrance examination, held leadership positions and participated in competitions, he was made the head of a group in the class. This entailed leading older students in group activities, an experience he called “challenging.” But that didn’t discourage him. After graduating from Bengbu Medical College at the age of 20, he went on to earn a master’s degree at Wuhan University School of Medicine, where he then worked as a faculty member for five years. At 28, he left China to move to Ohio with only two suitcases. There, Mei earned a Ph.D. in molecular biology and biochemistry from the University of Toledo. He then completed fellowships at the University of California, San Francisco and UC Berkeley; held leadership positions at Bayer, Biogen and Sanofi; and co-invented an approved drug, Jivi, an injectable medicine from Bayer for people with hemophilia A. Mei’s laundry list of accomplishments goes on. But he said that one of the most rewarding successes of his career is seeing patients in clinical trials that he runs sign on for an extension. He explained that this usually means patients feel like the drug is working for them without too many complications, which is a huge success in the R&D world. It’s happened many times throughout his career, he said, the first time with a hemophilia B drug at Biogen that was later approved by the FDA and marketed as Alprolix. Learning to Adapt Mei’s position at early-stage biotech Editas is more entrepreneurial than his earlier career, allowing him to remain close to the science and to clinical trials. But after coming from academia and Big Pharma, learning how to operate in a genome editing biotech with a few hundred employees involves a learning curve, he said. Fortunately for him, his formula for success is all about continuously learning and adapting. The most valuable thing he’s learned since starting at Editas in 2022 is how to communicate in a way that inspires confidence in the company, he said, so that stakeholders know that it has a solid strategy and can deliver helpful products. He’s been part of the executive leadership team working to transform Editas from a technology platform company to a commercial therapeutics company and leader in in vivo programmable gene editing. The team made changes to sharpen the company’s strategic focus and emphasize execution of clinical programs. “When you become a CMO in a private company, in addition to driving all these clinical trials, you also [have to think about] how the company can grow and what is the strategy of the company so that [it] can help more patients and help the stakeholders of the company,” he said. With these additional responsibilities, “I feel that I’m able to make more impact, not only to the company, [but] to the patients.” Mei categorizes the challenges he’s encountered in his career into two types: cultural and career-related. Most of his cultural challenges happened when he first came to the U.S. and had to adapt to food, language, TV, interpersonal interactions and many other aspects of daily life that were completely different from China. And his cultural environment has varied greatly even throughout his time in the U.S., he said, since he’s now lived in the Midwest and on both coasts. “The education system in China really . . . set a foundation for me to be able to adapt here in United States,” he said, by emphasizing math, physics and chemistry, and putting a lot of value on hard work and discipline. For example, in high school, he often studied past midnight and in medical school he had over 30 hours of classes each week. “This allowed me to really focus on learning and be humble, and that really helped me a lot.” When he first came to the U.S. for his Ph.D., it was uncertain whether he would be able to remain in the country to work after his student visa period. So he viewed it as an experiment, completing his Ph.D. without knowing how the rest of his career would turn out. If he couldn’t stay in the U.S., his backup plan was to bring his learning back to China. “And now, of course, after more than 30 years, I feel I’m American,” he said. “I feel the United States has given immigrants like myself so many opportunities. I feel so grateful for that . . . this is actually an amazing place [that] can provide people opportunity. And I understand why many people want to come.” Mollie Barnes is a freelance science writer based in Los Angeles. Reach her at mollie@100yearsco.com. Follow her on Threads and Instagram @shejustlikedtogo and see more of her work at molliebarnes.contently.com.

上市批准高管变更

2023-10-31

·PRNewswire

Octapharma AG: Indirect comparison data indicate that personalised prophylaxis with Nuwiq® may lead to fewer patients with haemophilia A having bleeds than with other recombinant factor VIII products

The well-established matching-adjusted indirect comparison (MAIC) methodology was used to compare the efficacy of personalised prophylaxis with Nuwiq® against other recombinant FVIII products Personalised prophylaxis with Nuwiq® can lead to higher rates of patients with zero bleeds compared with other recombinant FVIII products, albeit with higher weekly doses The data were published recently in the European Journal of Haematology LACHEN, Switzerland, Oct. 31, 2023 /PRNewswire/ -- Data from a matching-adjusted indirect comparison (MAIC) of Nuwiq® (simoctocog alfa) versus extended half-life recombinant factor VIII (rFVIII) concentrates in haemophilia A patients undergoing personalised prophylaxis were published in the European Journal of Haematology1. Preliminary data from the MAIC were presented by Dr Craig Kessler, Lombardi Comprehensive Cancer Center and Georgetown University Medical Center, at the 65th ASH Annual Meeting & Exposition in December 20222. Continue Reading Octapharma AG: Indirect comparison data indicate that personalised prophylaxis with Nuwiq® may lead to fewer patients with haemophilia A having bleeds than with other recombinant factor VIII products The analysis used MAIC – a well-established statistical approach – to compare the efficacy of pharmacokinetic (PK)-guided, personalised prophylaxis with Nuwiq® (simoctocog alfa) versus Eloctate® (efmoroctocog alfa), Jivi® (damoctocog alfa pegol), and Adynovate® (rurioctocog alfa pegol). The analysis used data from prospective clinical trials of personalised prophylaxis in adults with severe haemophilia A. Dr Kessler commented, "This MAIC exercise provides important comparative data on the efficacy and consumption of various recombinant FVIII products in adults with haemophilia A on personalised prophylaxis. The results can be considered by clinicians and patients when treatment decisions are being made." MAICs are a way of comparing the efficacy of different medical interventions or products in the absence of head-to-head randomised trials3. By matching patient populations based on clinically relevant baseline characteristics, it reduces inherent differences between the studies and can provide comparative evidence of relative treatment effects. Individual patient data from patients treated with Nuwiq® in the NuPreviq study were compared with aggregated data from 117 patients treated with Eloctate® in the personalised prophylaxis arm of the A-LONG study, 110 patients treated with Jivi® in the PROTECT VIII study, and patients treated with Adynovate® in the PROPEL study (which had two arms targeting different FVIII trough levels: 1–3% (57 patients) and 8–12% (58 patients)). A significantly higher percentage of patients with zero bleeds was reported with Nuwiq® compared with Eloctate® (75% vs 45%), Jivi® (77% vs 38%) or Adynovate® (target trough level 1–3%; 78% vs 42%). The efficacy of Nuwiq® was similar to that of Adynovate® in the 8–12% arm (77% vs 62%). The mean annualised bleeding rate was significantly lower with Nuwiq® than with Jivi® (1.5 vs 4.9). Consistent with the approved dosing, the mean FVIII weekly dose was significantly higher for Nuwiq® than Eloctate®, Jivi® or Adynovate® 1–3%, but lower than for Adynovate® 8–12%. Further details of the study can be found in the European Journal of Haematology publication. In addition, a short video summarising the results is available in the online version of the article. About Octapharma Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma employs more than 11,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Immunotherapy, Haematology and Critical Care. Octapharma has seven R&D sites and five state-of-the-art manufacturing facilities in Austria, France, Germany and Sweden, and operates more than 190 plasma donation centres across Europe and the US. Octapharma has 40 years of experience in patient care. About Nuwiq® Nuwiq® (simoctocog alfa) is a 4th generation recombinant factor VIII (rFVIII) protein, produced in a human cell line without chemical modification or fusion with any other protein4. It is cultured without additives of human or animal origin, is devoid of antigenic non-human protein epitopes and has a high affinity for von Willebrand factor4. Nuwiq® treatment has been assessed in nine4-6 completed clinical trials which included 201 previously treated patients (190 individuals)4 and 108 previously untreated patients5 with severe haemophilia A. Nuwiq® is available in 250 IU, 500 IU, 1,000 IU, 1,500 IU, 2,000 IU, 2,500 IU, 3,000 IU and 4,000 IU presentations7. Nuwiq® is approved for use in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital FVIII deficiency) across all age groups7. References Kessler CM et al. Eur J Haematol 2023; 111:757–67. Kessler CM and Tiede A. Blood 2022; 140(Suppl. 1): 2755–6. Signorovitch JE et al. Value Health 2012; 15:940–7. Lissitchkov T et al. Ther Adv Hematol 2019; 10:2040620719858471. Liesner RJ et al. Thromb Haemost 2021; 121:1400–8. Octapharma AG, data on file. Nuwiq® Summary of Product Characteristics. Logo - Video - SOURCE Octapharma AG

临床结果上市批准临床研究

2023-04-10

·BioSpace

HuidaGene Appoints New Members to the Scientific Advisory Board

SHANGHAI and CLINTON, N.J., Apr. 10, 2023 /PRNewswire/ -- HuidaGene Therapeutics (辉大基因; HuidaGene), a global clinical-stage biotechnology company focused on developing genomic medicine, today announced the selection of Drs. Haiyan Jiang and Alvin Luk as the new members of the Scientific Advisory Board (SAB). The SAB, which includes internationally renowned experts in gene and cell therapies, from discovery to translational research, and clinical development across different therapeutic areas, will provide strategic guidance for the global development of HuidaGene's expansive pipeline products. HuidaGene Appoints New Members to the Scientific Advisory Board "To meaningfully alter the course of genetic diseases, we must advance better-validated therapeutic candidates," said Dr. Haiyan Jiang. "My longstanding interest and commitment in gene and cell therapies have led me to HuidaGene's technology platforms that offer a potential cure to diseases with high unmet medical needs, and I am eager to work with the HuidaGene team to move their pipeline forward." Dr. Alvin Luk stated, "In looking to the future of the field, I have been impressed with HuidaGene's innovative genome-editing platforms. Dr. Hui Yang has been a long-time leader in CRISPR-based DNA/RNA editing, and I expect that our mutual interests and complementary areas of expertise within gene and cell therapy will be a powerful engine for advancing, and even accelerating, the progess at HuidaGene." "We are honored to have an accomplished and diverse group of scientific and clinical experts join us as members of our SAB, who represent extensive experience and knowledge in gene and cell therapies, global drug development, and data-driven clinical trial design," said Hui Yang, PhD, Co-Founder, Chief Scientific Advisor, and Chairman of the SAB at HuidaGene. "Haiyan and Alvin are industry veterans who have achieved a number of 'firsts' in gene therapy clinical programs and who will bring deep and relevant development expertise to HuidaGene. With our scientific advisors' leadership, HuidaGene is poised to translate decades of scientific discovery in programmable genome medicines to people living with devastating diseases worldwide," said Xuan Yao, PhD, Co-Founder and Chief Executive Officer of HuidaGene. About HuidaGene - 辉大基因 HuidaGene Therapeutics (辉大基因) is a global clinical-stage biotechnology company focusing on discovering, engineering, and developing CRISPR-based genetic medicine to rewrite the future of genomic medicine. Based in Shanghai and New Jersey, HuidaGene is committed to addressing patients' needs globally with various preclinical therapeutic programs covering ophthalmology, otology, myology, and neurology. We are currently advancing clinical programs in RPE65 mutation-associated inherited retinal diseases and our preclinical pipeline, including programs in neovascular age-related macular degeneration, retinitis pigmentosa, hereditary hearing loss, Duchenne muscular dystrophy, and MECP2 duplication syndrome. Company's CRISPR-based therapeutics offer the potential to cure patients with life-threatening conditions by repairing the cause of their disease. HuidaGene is committed to transforming the future of genome-editing medicine. For more information, please visit or follow us on LinkedIn at Details of the additional SAB members' biographies: Haiyan Jiang, Ph.D. has over 20 years of research and development expertise in biologics, AAV-mediated gene therapy, and in-vivo and ex-vivo CRISPR/Cas9- mediated genome editing products from research to BLA. She has held leadership roles with progressive responsibilities at various companies including Editas Medicine, Biogen, Bayer HealthCare, and Avigen. She led research, preclinical development or clinical pharmacology in the development of ALTUVIIIO, ELOCTATE, ALPROLIX, and JIVI, as well as a number of programs in Phase 1/2a studies. She has over 40 original publications in highly-regarded peer-reviewed journals, including New England Journal of Medicine, Nature Medicine, and Blood; as well as 21 issued US patents. Dr. Jiang received her B.S. in Biochemistry from Fudan University in Shanghai, China, Ph.D. in Oncology from University of Wisconsin-Madison, and postdoctoral training at the University of California-San Francisco. Alvin Luk, Ph.D., M.B.A., C.C.R.A. brings over 30 years' experience in global drug development, from the bench to the beside through successful commercial launch in small, large, public, and private biotech/biopharma firms, including Shanghai Henlius, Spark Therapeutics (acquired by Roche), Biogen, Bayer HealthCare, Avigen, and Tularik (acquired by Amgen). He is a transformational leader with reputation for navigating through political landscape which leads to a proven track record of more than 250 cumulative total of IND, BLA, and MAA submissions in Americas, Europe, Australia, Japan, and China. Spark Therapeutics' LUXTURNA was approved by US FDA as the first gene therapy in 2017 when he severed as the Head of Clinical Research and Operations. Today, he has participated in the development of 21 approved products. He is the co-author of more than 100 book chapters and scientific papers in highly-regarded peer-reviewed journals, including New England Journal of Medicine, Nature Medicine, Nature, Cell, and Science. Dr. Luk holds an MBA from Harvard Business School and received his Ph.D. in Neuroscience as well as being certified in clinical research from the University of California-San Francisco.

上市批准高管变更基因疗法并购

100 项与 Damoctocog Alfa Pegol 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10759	-	B02BD02	DB14700

研发状态

适应症	最高研发状态	国家/地区	公司
血友病A	批准上市	挪威更多	Bayer AG 更多
出血	临床3期	挪威更多	Bayer AG 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04085458 (CTgov)	临床4期	血友病A	32	BAY94-9027	夢壓窪糧顧鏇願鹽獵繭(獵簾製簾鹹顧積構鑰製) = 衊餘製觸繭餘蓋選簾襯選願齋鬱壓齋憲鹽積範 (餘願齋蓋網廠淵積繭觸, 製網衊膚淵艱鹹積範鹽 ~ 齋顧壓醖鏇觸憲齋製獵) 更多	-	2023-06-28
ISTH2023	N/A	-	10	Damoctocog alfa pegol	顧鬱窪顧顧網餘糧觸顧(夢簾簾選遞築憲衊積餘) = 廠淵選顧鹹廠糧鑰積夢鬱鑰壓蓋夢鬱餘鏇簾繭 (廠齋夢構築鹽艱糧鏇醖 ) 更多	-	2023-06-24
ISTH2023	N/A	血友病A	-	BAY 94-9027	遞衊齋構醖鑰製願壓繭(膚醖鹽鹽範淵蓋顧繭獵) = 淵窪餘醖築簾壓鹽艱衊淵鹽襯遞餘範鹽製餘繭 (願構選遞繭壓餘遞醖鹹 )	积极	2023-06-24
ISTH2023	N/A	血友病A	-	BAY 81-8973	遞衊齋構醖鑰製願壓繭(膚醖鹽鹽範淵蓋顧繭獵) = 範鑰夢糧膚糧憲廠顧構淵鹽襯遞餘範鹽製餘繭 (願構選遞繭壓餘遞醖鹹 )	积极	2023-06-24
HEM-POWR Study (ISTH2022)	N/A	血友病A	162	Damoctocog alfa pegol	壓夢壓簾觸膚齋範構簾(窪選蓋製鑰憲膚夢鏇範) = 衊觸壓夢選鹽壓糧鏇觸築壓廠窪觸廠願構廠築 (簾齋築鏇選顧餘積鏇製 )	积极	2022-07-09
ISTH2021	N/A	血友病A	134	BAY 94-9027	顧夢淵餘鑰淵壓糧積廠(遞網齋構範遞憲製鑰選) = 蓋選範艱艱繭鹽膚鹽襯鹹鹹衊鏇遞鬱鑰淵餘窪 (鏇壓簾願鬱鑰蓋鹽鏇壓 )	积极	2021-07-17
NCT01580293 (PROTECT VIII, ISTH2020)	临床2/3期	血友病A	114	BAY 94-9027 prophylaxis every 5 days	網蓋餘齋衊憲鏇膚願簾(醖製鏇膚餘遞襯鹽遞簾) = 5 (13.9%) patients experienced non-serious treatment-emergent drug-related adverse events 鹹蓋鬱鏇餘糧鹽糧築觸 (鬱獵淵壓選鑰構艱廠願 )	积极	2020-07-12
NCT01580293 (PROTECT VIII, ISTH2020)	临床2/3期	血友病A	114	BAY 94-9027 prophylaxis every 7 days		积极	2020-07-12
PROTECT VIII (ISTH2020)	临床2/3期	血友病A	121	BAY 94-9027	鹹獵鹽獵齋遞築艱鏇構(網餘襯窪遞窪蓋襯鹹構) = 積製鏇鬱製鏇襯鏇鏇艱餘構衊網蓋觸淵簾壓遞 (構鑰膚鹹壓衊淵廠鑰製 ) 更多	-	2020-07-12
NCT01580293 (PROTECT-VIII, Pubmed \| J Thromb Haemost) 人工标引	临床2/3期	血友病A	132	BAY 94-9027 (every-5-days (45-60 IU kg-1 ))	選積壓齋憲鑰餘鏇繭膚(糧膚膚製繭廠獵製積齋) = 鬱範積蓋窪願壓淵廠壓網鏇餘製鏇獵範膚願範 (廠製構糧觸構窪顧繭廠 )	积极	2017-03-01
NCT01580293 (PROTECT-VIII, Pubmed \| J Thromb Haemost) 人工标引	临床2/3期	血友病A	132	BAY 94-9027 (every-7-days (60 IU kg-1 ))	選積壓齋憲鑰餘鏇繭膚(糧膚膚製繭廠獵製積齋) = 淵鑰膚願繭衊餘醖鹽壓網鏇餘製鏇獵範膚願範 (廠製構糧觸構窪顧繭廠 )	积极	2017-03-01
NCT01184820 (Pubmed \| J Thromb Haemost)	临床1期	血友病A	14	BAY 94-9027	繭積憲蓋鬱構範鹹顧膚(鑰衊鑰膚鬱積鏇選構鬱) = 顧窪鬱觸憲獵鏇簾觸鹹簾膚簾顧膚簾壓選構壓 (齋製膚醖壓獵糧願憲廠 )	-	2014-04-01
NCT01184820 (Pubmed \| J Thromb Haemost)	临床1期	血友病A	14	sucrose-formulated rFVIII (rFVIII-FS)	繭積憲蓋鬱構範鹹顧膚(鑰衊鑰膚鬱積鏇選構鬱) = 網齋齋窪願鏇鹽蓋蓋積簾膚簾顧膚簾壓選構壓 (齋製膚醖壓獵糧願憲廠 )	-	2014-04-01